Genmab A/S announced FDA granted a Priority Review for the supplemental Biologics License Application for the use of daratumumab (Darzalex) in combination with bortezomib, thalidomide, and dexamethasone as treatment for patients newly diagnosed with multiple myeloma who are candidates for autologous stem cell transplant.
FDA grants Priority Review for daratumumab combination in multiple myeloma
YOU MAY BE INTERESTED IN
President Joe Biden April 9 announced his FY2022 budgetary plans for ARPA-H—Advanced Research Projects Agency-Health—a federal entity designed to “deliver breakthroughs to find cures for cancer and other diseases.” In his initial White House budget proposal—dubbed skinny budget, or budget-lite—Biden is requesting $6.5 billion to fund ARPA-H. “The discretionary request calls for $6.5 billion to...
Today Dr. Roswell Park is remembered mostly as the founder of the world’s first cancer research institute, which still bears his name proudly to this day in Buffalo, NY, but his contributions to medicine extend much further.